Seattle vaccine developer raises $18M in Series A
Seattle-based Immune Design has raised an impressive $18 million in its first round of venture capital. The vaccine company is developing therapies targeting dendritic cells, which control the human immune response system. And its researchers plan to develop new vaccines as well as enhance existing therapies. The company only has three full time staffers, but Immune Design says it will quickly expand to 30. And the developer has already attracted some top venture capital groups. Alta Partners, The Column Group and Versant Ventures all participated in the round.
- check out the company's release
- read the story from the Seattle Post-Intelligencer
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
- Forecast Model: Antidyslipidemics - Genericization and negative trial data drive market shrinkage
